Skip to main content
. 2017 Apr 29;8(32):52584–52593. doi: 10.18632/oncotarget.17526

Figure 4. Combination of gefitinib and HER3 siRNA inhibits the PI3K/AKT and ERK signalling pathways.

Figure 4

MKN45 and MKN45-HER3.3 cells were treated with 20 μM gefitinib. After 48 h of treatment, AKT and ERK activation is simultaneously ablated by the combination compared with the single treatments and the control. HER3.3 yields a greater inhibition of p-AKT than gefitinib.